US Pharm. 2014;39(10):7.
Geneva, Switzerland—The World Health Organization (WHO) is coordinating efforts with pharmaceutical companies and regulators to begin small-scale use of two experimental Ebola vaccines in West Africa by early next year. GlaxoSmithKline has begun clinical trials of its vaccine in the United States, Great Britain, and Mali, while NewLink vaccine trials are underway in the U.S. and Germany. The experimental vaccines have shown promising results in monkeys, and if results from these human trials are positive, limited vaccinations could be given in affected countries starting in January. There is currently no cure for Ebola, which has killed more than 3,000 people since the outbreak began last March. [As of 10/16/14: approximately 4,500 deaths; the numbers continue to rise.]
To comment on this article, contact firstname.lastname@example.org.